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Abstract 
 
Objective 
Risk alleles for type 2 diabetes at the STARD10 locus are associated with lowered STARD10 
expression in the β-cell, impaired glucose-induced insulin secretion and decreased circulating 
proinsulin:insulin ratios. Although likely to serve as a mediator of intracellular lipid transfer, the 
identity of the transported lipids, and thus the pathways through which STARD10 regulates β-
cell function, are not understood. The aim of this study was to identify the lipids transported and 
affected by STARD10 in the β-cell and its effect on proinsulin processing and insulin granule 
biogenesis and maturation. 
Methods 
We used isolated islets from mice deleted selectively in the β-cell for Stard10 (βStarD10KO) 
and performed electron microscopy, pulse-chase, RNA sequencing and lipidomic analyses. 
Proteomic analysis of STARD10 binding partners was executed in INS1 (832/13) cell line. X-ray  
crystallography followed by molecular docking and lipid overlay assay were performed on 
purified STARD10 protein. 
Results 
βStarD10KO islets had a sharply altered dense core granule appearance, with a dramatic increase 
in the number of “rod-like” dense cores. Correspondingly, basal secretion of proinsulin was 
increased. Amongst the differentially expressed genes in βStarD10KO islets, expression of the 
phosphoinositide binding proteins Pirt and Synaptotagmin 1 were decreased while lipidomic 
analysis demonstrated changes in phosphatidyl inositol levels. The inositol lipid kinase PIP4K2C 
was also identified as a STARD10 binding partner. STARD10 bound to inositides 
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phosphorylated at the 3’ position and solution of the crystal structure of STARD10 to 2.3 Å 
resolution revealed a binding pocket capable of accommodating polyphosphoinositides.  
Conclusion 
Our data indicate that STARD10 binds to, and may transport, phosphatidylinositides, influencing 
membrane lipid composition, insulin granule biosynthesis and insulin processing. 
 
Keywords: Type 2 diabetes; pancreatic β-cell; lipid transporter; insulin granule biogenesis; 
phosphoinositides 
 
 
 
Abbreviations: BUDE: Bristol University Docking Engine; GFP: Green Fluorescent Protein; 
GWAS : Genome Wide Association Study; KATP: ATP-sensitive K+ channels; HRP: Horseradish 
Peroxidase; Kir6.2: Kcnj11: Potassium Inwardly Rectifying Channel Subfamily J Member 11; 
KOMP: NIH Knock-Out Mouse Project; ICP/MS: Inductively coupled plasma mass 
spectrometry; IMPC: International Mouse Phenotyping Consortium; LPC: 
Lysophosphatidylcholine; MBP: Maltose Binding Protein; PC: Phosphatidylcholine; PE: 
Phosphatidylethanolamine; PI: Phosphatidylinositol; PI(3)P: Phosphatidylinositol 3-phosphate; 
PI(4,5)P2: PIP2, Phosphatidylinositol 4,5-bisphosphate; PI(5)P: Phosphatidylinositol 5-
phosphate; PIP: phosphatidylinositol phosphate, phosphatidylinositide; Pip4k2c: 
phosphatidylinositol 5-phosphate 4-kinase type-2 gamma; Pirt: phosphoinositide-interacting 
regulator of transient receptor potential channels; RNAseq: RNA sequencing; Ptbp1: 
Polypyrimidine tract-binding protein 1; Slc30a8: ZnT8, Solute Carrier Family 30 Member 8; 
SNARE: Soluble N-ethylmaleimide sensitive factor Attachment protein Receptor; STARD10: 
StAR Related Lipid Transfer Domain Containing 10; Syt1: Synaptotagmin 1; Sytl4: 
synaptotagmin-like 4, granuphilin;  TMT: Tandem Mass Tag; TRP: Transient receptor potential. 
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1. Introduction 
  
Diabetes mellitus is characterised by high blood glucose and currently affects around 8.5% of the 
population worldwide [1]. Normal glucose homeostasis requires the processing of proinsulin and 
the storage of the mature hormone within dense core granules in the pancreatic β-cell [2]. 
Glucose-induced insulin secretion involves glucose uptake and metabolism through the 
glycolytic pathway, increased ATP production by the mitochondria and the closure of ATP-
sensitive K+ channels (KATP). Subsequent depolarization of the plasma membrane leads to 
opening of voltage-gated Ca2+ channels, Ca2+ dependent assembly of the SNARE (SNAP 
(Soluble NSF Attachment Protein) Receptor) complex and exocytosis [3]. In the intact islet, β-
cell-β-cell connections allow coordinated insulin secretion through propagation of Ca2+ and other 
signals [4,5,6] a process impaired by glucolipotoxicity [7], and affected by genes implicated in 
diabetes risk through genome-wide association studies (GWAS) such as ADCY5 [8] and TCF7L2 
[9].   
We have recently examined a T2D-associated locus adjacent to STARD10 on chromosome 11q13 
[10,11]. Risk variants at this locus were associated with a decrease in STARD10 mRNA in 
human islets, with no concomitant change in the liver. Changes in the expression of the nearby 
ARAP1 gene were not associated with the possession of risk alleles in either tissue, pointing to 
STARD10 as the mediator of the effects of risk variants. Providing further compelling evidence 
for STARD10 as an “effector” gene, mice deleted for Stard10 specifically in the β-cell 
recapitulated the features observed in the human carriers of the risk allele, with an increase in fed 
glycemia and a decrease in the plasma proinsulin:insulin ratio. Islets isolated from the knock-out 
mice also showed impaired glucose-induced Ca2+ signalling and insulin secretion. Thus, β-cell 
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STARD10 may be a useful therapeutic target in some forms of type 2 diabetes, particularly in 
risk allele carriers who may benefit from a tailored, pharmacogenetic approach. 
STARD10 (previously named phosphatidylcholine transfer protein-like, Pctp-l) is a phospholipid 
transfer protein possessing a steroidogenic acute regulatory protein (StAR)-related lipid transfer 
(StART) domain that facilitates the transport of phosphatidylcholine and 
phosphatidylethanolamine between intracellular membranes [12]. Nevertheless, the molecular 
mechanisms by which STARD10 regulates insulin secretion in the β-cell, as well as its 
subcellular localisation and target membranes, remain unknown. We therefore examined in detail 
here the role of STARD10 in controlling the lipid composition, granule maturation, proinsulin 
processing and metal ion homeostasis in the mouse β-cell. We reveal an unexpected role for 
STARD10 in binding inositol phospholipids which may contribute to both secretory granule 
biogenesis and intracellular signalling. 
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2. Material and methods 
2.1. Generation and use of Stard10 null mice 
 All animal procedures were approved by the U.K. Home Office according to the Animals 
(Scientific Procedures) Act 1986 of the United Kingdom (PPL PA03F7F0F to I.L.). Stard10 
whole body and conditional KO mice (C57BL/6NTac background) were generated by the trans-
NIH Knock-Out Mouse Project (KOMP) and obtained from the KOMP Repository via the 
international mouse phenotyping consortium (IMPC). Mice homozygous for floxed Stard10 
(Stard10fl/fl) alleles were crossed to mice expressing Cre recombinase from the endogenous Ins1 
locus (Ins1-Cre mice). This generated Stard10fl/fl:Ins1Cre+ (βStard10KO) mice as in [10].  
  
2.2. Islet isolation and culture 
Mice were euthanized by cervical dislocation and pancreatic islets isolated by collagenase 
digestion as previously described [13] and cultured in RPMI 1640 medium, 11 mM glucose, 
supplemented with 10% (v/v) fetal bovine serum plus penicillin (100 units/mL) and streptomycin 
(0.1 mg/mL) at 37°C in an atmosphere of humidified air (95%) and CO2 (5%). 
 
2.3. Transmission electron microscopy imaging 
For conventional EM, islets were chemically fixed in 2% paraformaldehyde (EM grade), 2% 
glutaraldehyde and 3 mM CaCl2 in 0.1 M cacodylate buffer for 2 h at room temperature then left 
overnight at 4°C in fresh fixative solution, osmicated, enrobed in agarose plugs, dehydrated in 
ethanol and embedded on Epon. Epon was polymerised overnight at 60°C. Ultrathin 70 nm 
sections were cut with a diamond knife (DiATOME) in a Leica Ultracut UCT ultramicrotome 
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before examination on an FEI Tecnai G2 Spirit TEM. Images were acquired in a charge-coupled 
device camera (Eagle), and processed in ImageJ. 
 
2.4. Measurements of islet Zn2+ concentrations 
2.4.1. Cytosolic free Zn2+ measurements 
Imaging of cytosolic [Zn2+] using the eCALWY4 sensor was carried out on mouse islets 
dispersed onto coverslips as previously described [14]. Cells were maintained at 37°C and 
Krebs-HEPES-bicarbonate buffer (11 mM) was perifused with additions as stated in the figure. 
Images were captured at 433 nm monochromatic excitation wavelength. Acquisition rate was 20 
images/min.  
Image analysis was performed with ImageJ software [15] using a homemade macro and the 
fluorescence emission ratios were derived after subtracting background. We observed that during 
acquisition, photobleaching gradually decreased the steady-state ratio with a linear kinetic (not 
shown). This drift was thus, when necessary, corrected in function of time with a constant factor.  
 
2.4.2. Measurement of islet zinc content by inductively coupled plasma mass spectrometry 
(ICP-MS)  
Mouse islets were washed twice in PBS and stored at -80˚C until ready to process. Islets were 
lysed in 100 μL nitric acid (trace metal grade) and heated at 50˚C for 6 hours. The samples were 
then cooled, diluted in trace metal grade water up to a final volume of 1.3 mL and 10 μL of 1000 
ppb mix of 5 internal standards (bismuth, indium, scandium, terbium, and yttrium) was added. 
Standards between 0.5 and 500.5 μg/L of Zn were used for calibration. Samples were run on the 
Perkin Elmer NexION 350D using the Syngistix software. 
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2.5. Metabolic labelling of mouse pancreatic islets 
Islets isolated from βStard10KO and WT littermate mice were recovered overnight in RPMI-
1640 medium containing 11 mM glucose plus 10% FBS and penicillin-streptomycin. In each 
case, 50 islets were washed twice in prewarmed RPMI lacking cysteine and methionine. Islets 
were pulse-labeled with 35S-labeled amino acids for 20 min and chased for 1.5 h or 4 h in 5 mM 
glucose RPMI-1640 plus 10% FBS, Hepes, Pyruvate and penicillin-streptomycin. Islets were 
lysed in radioimmunoprecipitation assay buffer (25 mmol/L Tris, pH 7.5; 1% Triton X-100; 
0.2% deoxycholic acid; 0.1% SDS; 10 mmol/L EDTA; and 100 mmol/L NaCl) plus 2 mmol/L 
N-ethylmaleimide and protease inhibitor cocktail. Both cell lysates and media were precleared 
with pansorbin and immunoprecipitated with anti-insulin antibodies and protein A agarose 
overnight at 4˚C. Immunoprecipitates were analyzed using tris-tricine-urea-SDS-PAGE under 
nonreducing conditions or SDS-PAGE on 4-12% acrylamide gradient gels (NuPAGE) under 
reducing conditions as indicated with phosphorimaging. Bands were quantified using ImageJ 
software. 
 
2.6. In vitro proinsulin and insulin measurements 
Islets (10/well) were incubated in triplicate for each condition and treatment. Islets were pre-
incubated for 1 h in 3 mM glucose Krebs-Ringer-Hepes-Bicarbonate (KRH) buffer prior to 
secretion assay (30 min.) in 3 mM or 17 mM glucose. The secretion medium were then collected 
to measure the insulin and proinsulin concentrations using respectively an insulin HTRF kit 
(Cisbio Bioassays) and a rat/mouse proinsulin ELISA kit (Mercodia). 
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2.7. Lipidomic analysis 
Islets isolated from βStard10KO and WT littermate mice were recovered overnight in RPMI-
1640 medium containing 11 mM glucose plus 10% FBS and penicillin-streptomycin. Islets were 
then washed twice in PBS, snap-frozen in a bath of ethanol and dry ice and kept at -80˚C until 
ready to process. Lipids were extracted with 100 µl 1-butanol/methanol (1:1, v/v) containing 
2.5 µL of SPLASH™ Lipidomix® Mass Spec Standard I and 2.5 µL Cer/Sph Mixture I, 
purchased from Avanti Polar Lipids. The mixture was vortexed for 30 s, sonicated for 30 min. at 
20°C and then centrifuged at 14,000 g for 10 min. The supernatant was transferred into vials. 
The lipidomic analysis was performed by the Singapore Lipidomics Incubator (SLING) using an 
Agilent 1290 Infinity II LC system combined with an Agilent 6495 triple quadrupole mass 
spectrometer. Reverse Phase chromatographic separation of 1 µL samples were carried out on an 
Agilent Zorbax RRHD Eclipse Plus C18, 95 Å (50 x 2.1 mm, 1.8 µm) column maintained at 
40°C. The mobile phases consisted of (A) 10 mmol/L ammonium formate in acetonitrile/water 
(40:60, v/v) and (B) 10 mmol/L ammonium formate in acetonitrile/2-propanol (10:90, v/v). 
Using a flow rate of 0.4 mL/min. , the gradient elution program included 20% B to 60% B from 
0 to 5 min., 60 to 100% B from 2 to 7 min, where it was maintained till 9 min., then re-
equilibrated at 20% B for 1.8 min. prior to the next injection. All samples were kept at 10°C in 
the autosampler. The lipid amounts were normalised to protein content. MRM chromatograms 
obtained in positive ion mode, and covering >10 lipid classes, were processed using Agilent 
MassHunter Quantitative Analysis software (version B.08.00). Peaks were annotated based on 
retention time and specific MRM transitions. 
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2.8. Massive parallel sequencing of RNA (RNAseq) 
Total RNA was extracted with TRIzol from isolated mouse islets. Polyadenylated transcripts 
were selected during the preparation of paired-end, directional RNAseq libraries using the 
Illumina TruSeq Stranded mRNA Library Prep Kit. Libraries were sequenced on an Illumina 
HiSeq 4000 machine at 75 bp paired end. The quality of the sequenced libraries was assessed 
using fastQC. Reads were mapped to the Grc38m assembly using HiSat2. Annotated transcripts 
were quantified using featureCounts, and differentially expressed genes were identified with 
DESeq2. Raw sequence data for RNAseq will be made available via deposition to ArrayExpress. 
 
2.9. Purification and identification of STARD10 interacting proteins by mass spectrometry 
2.9.1. Co-immunoprecipitation 
INS1 (832/13) cells were lysed in the following non-denaturing lysis buffer: 20 mM HEPES, 150 
mM NaCl, 1% Igepal, protease inhibitors (Roche Diagnostics, complete, EDTA-free protease 
inhibitor cocktail tablets), phosphatase inhibitors (Sigma, P5726). 6 μg of Rabbit IgG isotype 
control (Abcam, ab171870) or anti-PCTP-L (STARD10) antibody (Abcam. ab242109) were 
bound to 50 μL of Dynabeads protein A for 1 h at 4˚C. For co-immunoprecipitation (Co-IP), 1 
mg of protein lysate was incubated with the complex beads-antibodies overnight at 4˚C. Beads 
were then washed twice in lysis buffer and twice in PBS-Tween 0.01% prior to proteomic 
analysis by the Bristol proteomics facility. 
 
2.9.2. TMT Labelling and High pH reversed-phase chromatography 
Pull-down samples were reduced (10 mM TCEP 55°C, 1 h), alkylated (18.75 mM 
iodoacetamide, room temperature, 30 min.) and digested on the beads with trypsin (2.5 µg 
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trypsin; 37°C, overnight), then labelled with Tandem Mass Tag (TMT) six plex reagents 
according to the manufacturer’s protocol (Thermo Fisher Scientific, Loughborough, LE11 5RG, 
UK) and the labelled samples pooled. 
The pooled sample was evaporated to dryness, resuspended in 5% formic acid and then desalted 
using a SepPak cartridge according to the manufacturer’s instructions (Waters, Milford, 
Massachusetts, USA).  Eluate from the SepPak cartridge was again evaporated to dryness and 
resuspended in buffer A (20 mM ammonium hydroxide, pH 10) prior to fractionation by high pH 
reversed-phase chromatography using an Ultimate 3000 liquid chromatography system (Thermo 
Fisher Scientific).  In brief, the sample was loaded onto an XBridge BEH C18 Column (130 Å, 
3.5 µm, 2.1 mm x 150 mm, Waters, UK) in buffer A and peptides eluted with an increasing 
gradient of buffer B (20 mM Ammonium Hydroxide in acetonitrile, pH 10) from 0-95% over 60 
minutes. The resulting fractions (4 in total) were evaporated to dryness and resuspended in 1% 
formic acid prior to analysis by nano-LC MSMS using an Orbitrap Fusion Tribrid mass 
spectrometer (Thermo Scientific). 
 
2.9.3. Nano-LC Mass Spectrometry 
High pH RP fractions were further fractionated using an Ultimate 3000 nano-LC system in line 
with an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific). In brief, peptides in 1% 
(vol/vol) formic acid were injected onto an Acclaim PepMap C18 nano-trap column (Thermo 
Scientific). After washing with 0.5% (vol/vol) acetonitrile 0.1% (vol/vol) formic acid peptides 
were resolved on a 250 mm × 75 μm Acclaim PepMap C18 reverse phase analytical column 
(Thermo Scientific) over a 150 min. organic gradient, using 7  gradient segments (1-6% solvent 
B over 1 min., 6-15% B over 58 min., 15-32%B over 58 min., 32-40%B over 5 min., 40-90%B 
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over 1 min., held at 90%B for 6 min. and then reduced to 1%B over 1 min.) with a flow rate of 
300 nl min−1. Solvent A was 0.1% formic acid and Solvent B was aqueous 80% acetonitrile in 
0.1% formic acid. Peptides were ionized by nano-electrospray ionization at 2.0 kV using a 
stainless steel emitter with an internal diameter of 30 μm (Thermo Scientific) and a capillary 
temperature of 275°C. 
All spectra were acquired using an Orbitrap Fusion Tribrid mass spectrometer controlled by 
Xcalibur 3.0 software (Thermo Scientific) and operated in data-dependent acquisition mode 
using an SPS-MS3 workflow. FTMS1 spectra were collected at a resolution of 120 000, with an 
automatic gain control (AGC) target of 400 000 and a max injection time of 100 ms. Precursors 
were filtered with an intensity range from 5000 to 1E20, according to charge state (to include 
charge states 2-6) and with monoisotopic peak determination set to peptide. Previously 
interrogated precursors were excluded using a dynamic window (60 s ± 10 ppm). The MS2 
precursors were isolated with a quadrupole isolation window of 1.2m/z. ITMS2 spectra were 
collected with an AGC target of 10 000, max injection time of 70ms and CID collision energy of 
35%. 
For FTMS3 analysis, the Orbitrap was operated at 30 000 resolution with an AGC target of 50 
000 and a max injection time of 105 ms. Precursors were fragmented by high energy collision 
dissociation (HCD) at a normalised collision energy of 55% to ensure maximal TMT reporter ion 
yield. Synchronous Precursor Selection (SPS) was enabled to include up to 5 MS2 fragment ions 
in the FTMS3 scan. 
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2.9.4. Data Analysis 
The raw data files were processed and quantified using Proteome Discoverer software v2.1 
(Thermo Scientific) and searched against the UniProt Rat database (downloaded January 2019; 
35759 entries) using the SEQUEST algorithm. Peptide precursor mass tolerance was set at 10 
ppm, and MS/MS tolerance was set at 0.6 Da. Search criteria included oxidation of methionine 
(+15.9949) as a variable modification and carbamidomethylation of cysteine (+57.0214) and the 
addition of the TMT mass tag (+229.163) to peptide N-termini and lysine as fixed modifications. 
Searches were performed with full tryptic digestion and a maximum of 2 missed cleavages were 
allowed. The reverse database search option was enabled and all data was filtered to satisfy false 
discovery rate (FDR) of 5%. 
 
2.10. Lipid overlay assay 
All incubation steps were performed at room temperature. PIP strips (Thermo Scientific) were 
blocked for 1h in TBS containing 0.1% Tween-20 (TBS-T) supplemented by 3% fatty-acid free 
BSA (Sigma Aldrich) before incubation with the purified STARD10 protein (1 μg/mL in TBS-T 
+ 3% BSA) for 1 h. The membrane was washed 5 times 10 min. in TBS-T and probed for 1 h 
with the polyclonal goat anti-STARD10 antibody (Santa Cruz sc54336; 1/1000 in TBS-T + 
3%BSA). After 5 washes of 10 min. in TBS-T, the membrane was incubated 1 h with the 
horseradish peroxidase conjugated donkey anti-goat IgG (Santa Cruz sc2020; 1/2000 in TBS-T + 
3%BSA). After 5 washes of 10 min. in TBS-T, bound proteins were detected by ECL reagent 
(GE Healthcare). 
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2.11. Structure solution of STARD10 
2.11.1. Cloning 
The full length gene encoding human STARD10 protein was amplified from cDNA by PCR and 
cloned into a modified pET28a expression vector, pET28-HMT, which contains a fused N-
terminal 6×His-tag, an MBP-tag and a TEV protease recognition site (His-MBP-TEV) by In-
fusion® HD Cloning kit (Takara Bio, USA). The fidelity of the constructs was confirmed by gel 
electrophoresis and sequencing. 
 
2.11.2. Protein preparation  
In brief, transformed E. Coli BL21 (DE3) clones were grown at 37°C in LB medium containing 
50 μg/mL Kanamycin to an optical density at 600 nm of 0.8. Protein expression was induced at 
30°C for 4  h by adding isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 
0.5  mM. After harvesting, cells were re-suspended in lysis buffer (20  mM Tris (pH 8.0), 1  M 
NaCl and 0.5 mM TCEP) with protease inhibitor, lysed by sonication and centrifuged at 18,000 
× g for 60  min. at 4°C. The supernatant was loaded on a HisTrap HP column (GE Healthcare, 
Fairfield, CT), equilibrated with buffer A (20  mM Tris (pH 8.0), 1  M NaCl, 0.5 mM TCEP and 
5  mM imidazole), washed with 30 mM imidazole and finally eluted with 500 mM imidazole. 
After His-MBP-TEV-tag-removal using TEV protease, the protein was dialysed into buffer B 
(20  mM Tris (pH 8.0), 100  mM NaCl and 0.5 mM TCEP) and re-loaded onto the HisTrap HP 
column (GE Healthcare) to remove the tag, uncleaved protein and TEV protease. The flow-
through fractions were collected and loaded onto a MonoQ column (GE Healthcare) pre-
equilibrated with buffer B. Some E.coli background protein and DNA rather than STARD10 can 
bind on the MonoQ. Then the flow-through fractions were collected and loaded onto a Heparin 
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HP column (GE Healthcare) pre-equilibrated with buffer B. Fraction containing STARD10 
protein was eluted with a linear gradient from 250  mM to 800  mM NaCl. The protein was 
finally purified by Superdex 75 10/300 GL column (GE Healthcare) with buffer B. 
 
2.11.3. Crystallization and structure determination 
Crystallization trials were carried out by the sitting drop vapor diffusion method at 293  K. 
Freshly purified STARD10 was concentrated to ~38 mg/mL and centrifuged to remove insoluble 
material before crystallization. Single crystals appeared in condition containing 50% (v/v) PEG 
200, 100 mM Sodium phosphate dibasic/ Potassium phosphate monobasic (pH 6.2) and 200 mM 
NaCl after one month. Cryo-freezing was achieved by stepwise soaking the crystals in reservoir 
solution containing 10, 20, and 30% (w/v) glycerol for 3 min. and flash freezing in liquid 
nitrogen. X-ray diffraction data were collected on beamline I03 at the Diamond synchrotron X-
ray source, and were integrated and scaled with the Xia2 system [16]. 
Structure was determined by molecular replacement using the START domain structure from 
human STARD5 protein (PDB ID: 2R55) as search model in CCP4, followed by rigid-body 
refinement by Refmac5 [17]. Structure was refined using PHENIX [18] and interspersed with 
manual model building using COOT [19]. The structure contains one STARD10 molecule in the 
asymmetric unit. 245 out of 291 residues (STARD10 full length) were successfully built into the 
density in the final structure. The statistics for data collection and model refinement are listed in 
Supplemental Table 6. 
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2.12. Molecular docking of ligands in STARD10 and STARD2 
In silico molecular docking was performed using the Bristol University Docking Engine (BUDE 
1.2.9). Firstly, a set of conformations for the head groups, glycero-inositol-1-phosphate and 
glycero-3-phosphoinositol-1-phosphate were generated using OpenBabel (2.4.1) giving 87 and 
85 conformers respectively. The docking grid was centered on the central cavity in STARD2 
(1LNL) and STARD10 (6SER). Each conformer of the PI and PI(3)P headgroups was docked 
into both structures. Each docking run found the best solutions by sampling a total of 1.1 million 
poses via BUDE’s genetic algorithm. Final models were constructed by adding the 2 linoleoyl 
chains from the conformation in 1LN1 (STARD2 dilinoleoylphosphatidylcholine complex) and 
refined by energy minimisation with GROMACS. 
 
2.13. Statistics 
Data are expressed as mean ± SD. Normality of the data distribution was tested by D’Agostino 
and Pearson and Shapiro-Wilk normality tests. For normally distributed data, significance was 
tested by Student’s two-tailed t-test or Welch’s t-test if the variances were found significantly 
different by F-test. Mann-Whitney test was used for non-parametric data, and one-or two-way 
ANOVA with SIDAK multiple comparison test for comparison of more than two groups, using 
Graphpad Prism 7 software. p < 0.05 was considered significant. 
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3. Results 
3.1. Stard10 deletion affects dense core granule ultrastructure 
As an initial approach to determining the target membranes for STARD10 action, we first 
explored the impact of deleting the Stard10 gene on β-cell ultrastructure. We have previously 
shown that crossing of Stard10 floxed mice to Ins1Cre knock-in mice [20] efficiently and 
selectively deletes STARD10 in the pancreatic β-cell [10]. Transmission electron microscopy 
images of β-cells in islets isolated from βStard10KO mice revealed a dramatic change in insulin 
granule morphology with a significant increase in “atypical” granules with a “rod-shaped” core 
(Figure 1A and B; Cre+: 12.05 ± 1.67% versus Cre-: 2.78 ± 0.36%; p<0.001, Student’s t test, 
n = 3 animals). In addition, the mean granule diameter was decreased (Figure 1C; Cre+: 255.2 ± 
25.8 nm versus Cre-: 277.9 ± 24.9 nm; p<0.001, Student’s t-test, n = 42 images from 3 animals) 
and the “circularity” increased slightly (Figure 1D; Cre+: 0.89 ± 0.01 versus Cre-: 0.87 ± 0.03; 
p<0.05, Welch’s t-test, n = 42 images from 3 animals) in βStard10KO compared to WT 
littermate β-cells. However, the cytoplasmic abundance of granule profiles (“density”) (Figure 
1E; Cre-: 3.82 ± 1.80 vs. Cre+: 3.66 ± 0.61 granules/μm2; ns, Mann-Whitney test, n = 19 images 
from 3 animals) and the number of granules morphologically docked to the plasma membrane 
(Figure 1F; Cre-: 0.76 ± 0.43 vs. Cre+: 0.75 ± 0.28 granules/μm plasma membrane; ns, Mann-
Whitney test, n = 18 images from 3 animals; granules were considered morphologically docked 
if the distance from their centre to the plasma membrane was ≤ 200nm) remained similar in both 
genotypes. 
Analyses of transmission electron microscopy images of human β-cells from partially 
pancreatectomised patient samples (Supplemental Figure 1A and Supplemental Table 1) showed 
no significant correlation between STARD10 expression measured by RNAseq and the 
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percentage of mature granules (Supplemental Figure 1B) or the density of mature, immature or 
total granules (Supplemental Figure 1C). 
In conclusion, deleting Stard10 specifically in the β-cell in mice greatly affected insulin granule 
ultrastructure and overall shape with an increase in granules with a “rod-shaped” core.    
 
3.2. Islet zinc content is increased in βStard10KO mice 
To determine whether the abnormalities in granule structure may result from altered Zn2+ content 
of granules, itself a critical regulator of insulin crystallisation [2,21], we used the Förster 
resonance energy transfer- (FRET) based sensor eCALWY4 [14] to measure free Zn2+ 
concentration in the cytosol of dissociated islets from βStard10KO mice. The measured free 
cytosolic Zn2+ concentrations were similar in both genotypes (Figure 1G and H; ns; Mann 
Whitney test, n = 33–65 cells). On the other hand, total zinc, measured by inductively-coupled 
plasma mass spectrometry (ICP/MS) was higher in βStard10KO isolated islets compared to WT 
ones (Figure 1I: Cre-: 90.1 ± 55.15 vs. Cre+: 183.4 ± 38.73 μg/mL; p<0.05; unpaired t test, n = 4 
animals). 
 
3.3. Newly synthesised proinsulin is constitutively secreted by βStard10KO islets  
The characteristic decrease of plasma proinsulin:insulin ratio observed in human carriers of the 
risk alleles at this locus [22], and the observation of a similar phenotype in βStard10KO mice 
[10], suggest an action of STARD10 on proinsulin processing in the β-cell. We therefore next 
investigated this hypothesis by performing a metabolic labelling pulse-chase experiment in 
isolated islets from WT and βStard10KO mice.  
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After 20 min. of pulse-labelling with 35S-amino acids, the islets of both genotypes were chased 
for 1.5 or 4 h in 5.5 mM glucose medium. Insulin was immunoprecipitated from both the cell 
lysate (C) and the secretion media (M) (Figure 2A). Labeled proinsulin secretion by Cre+ islets 
was increased at low (5.5 mM) glucose compared to Cre- mice after 4 h of chase (Figure 2B; 
Cre-: 8.46 ± 2.11 vs. Cre+: 12.64 ± 2.42% total; *p<0.05, Mann Whitney test, n = 4-5 animals). 
This increase in basal proinsulin secretion in the KO islets tended to be observed from 1.5 h of 
chase (Figure 2B; Cre-: 6.60 ± 1.32 vs. Cre+: 9.58 ± 3.37% total; p = 0.064, Mann Whitney test, 
n = 4-5 animals). The secreted labelled proinsulin:insulin ratio was also increased after 1.5 h of 
chase (Figure 2C; Cre-: 0.85 ± 0.40 vs. Cre+: 2.05 ± 0.88; p<0.05, Mann Whitney test, n = 4-5 
animals), but no apparent change was noted in the labelled proinsulin:insulin ratio inside the 
cells (Figure 2D; 1.5 h: Cre-: 0.29 ± 0.07 vs. Cre+: 0.27 ± 0.04, 4 h: Cre- : 0.17 ± 0.06 vs. Cre+ : 
0.16 ± 0.04, ns, Mann Whitney test, n = 4-5 animals) or in the newly synthesised stored insulin 
remaining in the cells (Figure 2E; 1.5 h: Cre-: 0.56 ± 0.09 vs. Cre+: 0.61 ± 0.07; 4 h: Cre- : 0.45 
± 0.15 vs. Cre+ : 0.53 ± 0.07, ns, Mann Whitney test, n = 4-5 animals).  
A similar experiment was carried out where the islets were chased after 30 min. in 20 mM 
glucose (Figure 2F). Although the proinsulin secretion and the secreted proinsulin:insulin ratio 
from the KO islets at 20 mM glucose tended to be increased vs wild-type islets, values were not 
significantly different between genotypes (Figure 2G and H). It is worth noting that insulin 
granules ordinarily have a long lifespan in β-cells, with a half-life of several days, indicating that 
the labelled peptides observed in this experiment originate from young granules.   
In order to determine whether the increase in newly synthesised proinsulin secretion observed in 
the pulse-chase experiment reflected a change in total secreted proinsulin, we measured total 
insulin and proinsulin in the secretion medium after 30 min. in low (3 mM) or stimulating 
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(17 mM) glucose concentrations. However, the secreted proinsulin:insulin ratios remained 
unchanged between genotypes at both glucose concentrations (Figure 2I). 
 
3.4. Preserved glucose-regulated membrane potential and β-cell-β-cell connectivity in 
Stard10KO islets 
Our previous study [10] showed that deletion of Stard10 in the β-cell impaired glucose-induced 
cytoplasmic Ca2+ increases and insulin secretion. To test for a potential upstream defect, e.g. in 
the closure of ATP-sensitive K+ (KATP) channels [24], we performed perforated patch-clamp 
electrophysiology [25] to measure plasma membrane potential in dispersed single β-cells. No 
change in glucose-induced membrane depolarisation was observed in β-cells from βStard10KO 
animals compared to WT littermates (Supplemental Figure 2A,B).  
β-cell-β-cell connections are essential for synchronised intra-islet Ca2+ influx, and ultimately 
efficient insulin secretion [4]. We subjected the individual Ca2+ traces recorded from fluo-2-
loaded β-cells in the intact mouse islets to correlation (Pearson R) analysis to map cell-cell 
connectivity [7,8,26]. In the presence of low (3 mM) glucose, β-cells displayed low levels of 
coordinated activity in islets of WT and whole body Stard10KO animals, as assessed by 
counting the numbers of coordinated cell pairs (Supplemental Figure 3A,B; 21.70 ± 9.13% 
versus 18.95 ± 17.47% for WT versus KO, respectively, ns). By contrast, β-cells displayed 
highly coordinated Ca2+ responses upon addition of 17 mM glucose or 20 mM KCl (the latter 
provoking depolarisation and a synchronized Ca2+ peak; not shown) in WT islets. None of the 
above parameters were altered in KO islets (Supplemental Figure 3A,B; 17 mM G: 
98.61 ± 1.34% versus 92.23 ± 10.46% for WT vs KO; KCl: 92.63 ± 7.23% vs 93.36 ± 11.44% 
for WT vs KO, respectively; ns). Similarly, analysis of correlation strength in the same islets 
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(Supplemental Figure 3C,D) revealed no significant differences between genotypes. 
 
3.5. Altered lipidomic profile in βStard10KO islets   
To determine whether the observed changes in secretory granule ultrastructure (Figure 1A) might 
result from an altered lipid composition in Stard10-null β-cells, we performed targeted mass 
spectrometry. Total cholesteryl esters (Cre-: 1.60 ± 0.36 vs. Cre+: 2.24 ± 0.50% total lipids; 
**p<0.01, paired t-test) and phosphatidylinositols (PI) (Cre-: 7.63 ± 1.15 vs. Cre+: 8.98 ± 1.16% 
total lipids; *p<0.05, paired t-test) as well as a particular species of phosphatidylethanolamine 
(PE 34:0; Cre-: 0.019 ± 0.0029 vs. Cre+: 0.024 ± 0.0022% total lipids; *p<0.05, paired t-test)  
were all significantly increased in the KO islets vs. WT (Figure 3), suggesting that STARD10 is 
involved in the regulation of the turnover of these lipid species.  
      
3.6. Altered expression of genes controlling Ca2+ fluxes, exocytosis and inositol phospholipid 
signalling in βStard10KO islets 
In order to assess the effect of β-cell selective Stard10 deletion on the transcriptome, we 
performed massive parallel RNA sequencing (RNAseq) on islets from WT and βStard10KO 
mice. We identified 88 differentially regulated genes (padj<0.05, n = 6 animals), with 33 
upregulated and 55 dowregulated in KO versus WT islets. The list of the 20 most significantly 
regulated genes is presented in Figure 4A and Table 1 (padj ranging from 1.71x10-157 to  
2.25x10-3). As expected, a decrease in Ins1 expression in the Cre+ mice carrying an Ins1-Cre 
knock-in allele was observed. Interestingly, Scg2, encoding secretogranin 2, a member of the 
granin protein family, localised in secretory vesicles [27], and Rasd2, also known as Ras 
homologue enriched in striatum (Rhes), were upregulated. Suggesting possible changes in 
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phosphoinositide signalling, Pirt (phosphoinositide-interacting regulator of transient receptor 
potential channels), a regulator of transient receptor potential Ca2+ channels [28] and Syt1 
(synaptotagmin 1) regulating fast exocytosis and endocytosis in INS1 cells [29] were 
downregulated in βStard10KO islets. 
Enrichment analysis through the gene ontology consortium website 
(http://www.geneontology.org/) identified genes whose products are localised in neuronal 
projections (11 genes, fold enrichment = 4.57, p<0.05) and neurons (12 genes, fold enrichment 
= 3.95, p<0.05) among the down-regulated genes (Figure 4B, Supplemental Table 2). As 
secretory cells, neurons share their transport and secretory machinery with β-cells, suggesting 
that these genes play a role in the insulin secretion process. Among the genes identified, several 
are implicated in insulin secretion and/or β-cell survival: Chl1 (cell adhesion molecule L1-like), 
whose silencing has previously been shown to reduce glucose-induced insulin secretion in INS1 
cells [30] and is down regulated in islets from Type 2 diabetic subjects [31]; Nos1 (neuronal 
nitric oxyde synthase), implicated in insulin secretion and β-cell survival [32]; Adcyap1r1 
(adenylate cyclase activating polypeptide 1 receptor 1), encoding the PAC1 receptor of the 
pituitary adenylate cyclase activating polypeptide (PACAP) neuroendocrine factor [33] and 
Cplx1 (complexin 1) [34]. None of several key β-cell signature genes involved in the regulation 
of Ins expression and β-cell identity (Figure 4C), or of the “disallowed” β-cell gene family 
(Figure 4D) [3], were affected by Stard10 deletion. 
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3.6. STARD10 interactome analysis identifies proteins involved in phosphatidylinositide 
signalling    
Protein interacting partners of STARD10 were identified by immunoprecipitation of the 
endogenous protein in the rat pancreatic β-cell line INS1 (832/13) and liquid chromatography–
tandem mass spectrometry analysis after tandem mass tag (TMT) labelling of the digested 
samples. 303 significantly enriched proteins were detected in the STARD10 pull-down condition 
compared with the non-targetting control IgG (p<0.05 and FDR<0.05, paired t-test) (Table 2). 
Among these significant interactions, we observed proteins well known to play a role in β-cell 
physiology: the pore forming subunit Kir6.2 (Kcnj11, ATP-sensitive inward rectifier potassium 
channel 11) and its auxiliary subunit, the sulfonylurea receptor SUR1 (Abcc8, ATP-binding 
cassette sub-family C member 8) of the ATP-sensitive K+ (KATP) channel [35]; the 
phosphoinositide PI(4,5)P2-interacting protein Granuphilin (Sytl4; synaptotagmin-like 4) 
associates with and is involved in the docking of  the insulin granules [36]; the polypyrimidine 
tract-binding protein 1 (Ptbp1) is required for the translation of proteins localised in the insulin 
granule in response to glucose [37]. Gene ontology analysis of the identified STARD10 binding 
partners reflected an enrichment in proteins associated with RNA binding and processing, gene 
expression and splicing (Supplemental Tables 3, 4 and 5). 
 
Interestingly, STARD10 also interacted with the inositol lipid kinase phosphatidylinositol 5-
phosphate 4-kinase type-2 gamma (Pip4k2c) enzyme, which converts phosphatidylinositol 5-
phosphate (PI(5)P) into phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) [38].  
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3.7. STARD10 binds to phosphatidylinositides  
To assess which membrane lipids may be bound by STARD10, we generated and purified the 
recombinant protein from a bacterial expression construct comprising the human STARD10 
coding sequence fused with a 6His-MBP (Maltose Binding Protein) tag. Following recombinant 
protein production in E. coli and protein purification, we performed a lipid overlay assay, in 
which in vitro lipid binding to a range of phospholipids spotted onto a nitrocellulose membrane 
is assessed [39]. The efficiency and specificity of protein purification was monitored by SDS-
PAGE staining with Coomassie blue (Figure 5A). Purified STARD10 protein was incubated with 
the PIP membrane strips and detected using an anti-STARD10 antibody and secondary anti-goat-
HRP antibody (Figure 5B). Interestingly, STARD10 interacted with all PIP species interrogated, 
suggesting that STARD10 may bind to membranes containing these phospholipids.   
 
3.8. Resolution of STARD10 structure and molecular docking identify PI and PI(3)P as 
potential ligands  
The above lipid overlay assay reveals interaction with phospholipids but does not distinguish 
between surface binding and uptake of the lipid into the lipid binding pocket of the protein. In 
order to explore the potential binding of inositol phospholipids in this pocket, we sought to 
obtain a crystal structure of the purified protein. Purified STARD10 generated a well diffracting 
crystal. The crystal structure was then resolved at 2.3 Å resolution by molecular replacement 
using the structure of STARD5 (PDB ID: 2R55) (Figure 6A; Supplemental movie 1; 
Supplemental Table 6). 
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In the STARD10 crystal structure, the dimensions of the cavity are such that the protein is 
expected to readily accommodate phosphatidylinositols, whereas STARD2 cavity, due to its 
smaller size, gives poor predicted binding energy. On this basis, STARD10 binding pocket is 
expected to bind PI and various phosphorylated PIs with higher affinity than STARD2.  
The head groups of PI and PI(3)P (glycero-inositol-1-phosphate and glycero-3-phosphoinositol-
1-phosphate) were then docked into the 3-dimensional structure of STARD10 (described above) 
and the closer family member STARD2 [40] by using the Bristol University Docking Engine 
(BUDE) [41] (Figure 5B, supplemental movie 2). The software was used to dock different 
representative conformations of the ligand to the target protein: 87 conformers for PI and 85 for 
PI(3)P. When these conformers were docked to STARD10, all final poses were located inside the 
binding cavity. On the other hand, for STARD2, only two conformers were placed by BUDE 
inside the protein, the rest were docked onto the outer surface of the protein, suggesting that, 
contrary to STARD10, binding inside STARD2 by PI and PI(3)P is unfavourable. Likewise, the 
predicted binding energies of PI and PI(3)P headgroups to STARD10 is about 40 kJ mol-1 better 
than those to STARD2. 
   
To address which intracellular membranes may be affected by alterations in STARD10 
expression, and hence lipid distribution, we next performed confocal analysis of the subcellular 
localization of STARD10 tagged at the carboxy- or amino-terminus with green fluorescent 
protein (STARD10-GFP or GFP-STARD10). However, this indicated a largely homogeneous 
cytosolic and nuclear distribution (Supplemental Figure 4), precluding the identification of likely 
target membranes or organelles. 
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4. Discussion 
Our earlier demonstration [10] that STARD10 is the likely causal gene at the T2D risk locus on 
chromosome 11q13 has emphasised the probable importance of lipid transfer for the normal 
physiology of the pancreatic β-cell. Indeed, the role of lipid transfer proteins has emerged 
recently as an important element in cell biology [42].  
 
Several lines of evidence presented in our studies now support a role for STARD10 in PI/PIPs 
binding and potentially transport between intracellular membranes: (a) Resolution of the crystal 
structure of STARD10 and molecular docking predict binding of PI/PIPs in its binding pocket 
(Figure 6). (b) Purified recombinant STARD10 binds to phosphatidylinositide species in a lipid 
overlay assay (Figure 5). (c) The phosphatidylinositol content was increased in βStard10KO 
compared to control islets (Figure 3). (d) The expression of the phosphoinositide binding 
proteins Syt1 and Pirt were decreased in βStard10KO islets (Figure 4). Pirt encodes a 
phosphoinositide interacting regulator of the transient receptor potential (TRP) Ca2+ channels. 
Several TRP channels are expressed in the β-cell and an increasing amount of data points 
towards a role of these channels in the regulation of insulin secretion [43]. A previous study [44] 
has shown that female Pirt-/- mice are heavier than controls and develop glucose intolerance. 
(e) Our proteomic study identified the phosphatidylinositol 5-phosphate 4-kinase type-2 gamma 
(Pip4k2c) enzyme and the PI(4,5)P2-binding protein granuphilin [45] as STARD10 binding 
partners.   
 
Taken together, these data suggest that STARD10 may bind PI and/or PIPs either in the lipid 
binding pocket, as predicted by the crystal structure and molecular docking (Figure 6), or at the 
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surface of the protein. We note that the lipid overlay assay is consistent with a binding of 
STARD10 to membranes containing PIP lipids (with an affinity which appears higher for (3)P 
containing species). This could be important for the targeting of STARD10 to specific membrane 
compartments. In contrast to its closest relative STARD2, which has been shown to selectively 
bind phosphatidylcholine [46], our crystal structure determination and molecular docking 
indicate that STARD10, due to its larger binding pocket, is predicted to bind 
phosphatidylinositol (PI) and its various phosphorylated forms (PIPs) (Figure 6) in addition to its 
previously recognised ligands phosphatidylcholine and phosphatidylethanolamine [12].  
 
Consistent with likely mis-targeting of lipids to membranes involved in insulin secretion, we 
demonstrate that STARD10 is required for normal secretory granule maturation in murine β-
cells. Of note, recent findings [47] have indicated that cholesterol is also required for normal 
granule maturation. In addition, in INS-1 (832/13) cells, the insulin secretory granule was found 
to contain a high proportion of phosphatidylinositol (~20%, 5-fold that in the whole cell) [48]. In 
contrast, we were not able to obtain evidence for an effect of STARD10 variation on human β-
cell granules, perhaps reflecting a greater diversity in granule structure observed in man, as well 
as the limited number of subjects available for analysis.  
 
RNAseq analysis of the transcriptome of WT and βStard10KO islets identified differentially-
expressed genes which are likely to play a role in adult β-cell physiology (Figure 4). These 
include Syt1 (synaptotagmin 1) and Cplx1 (complexin 1), whose genes products are part of the 
molecular machinery driving vesicle exocytosis and form a tripartite complex with Soluble N-
ethylmaleimide sensitive factor Attachment protein Receptor (SNARE) proteins [49]. However, 
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none of these genes are readily linked to a change in insulin crystallisation or granule biogenesis. 
Importantly, we also identified Pirt, a phosphoinositide-interacting regulator of transient receptor 
potential channels, as a binding partner of STARD10 and thus likely either to sense or to 
influence phosphoinositides levels in cells. 
 
Proteomic analysis of the STARD10 binding partners in INS1(832/13) pancreatic β-cells (Table 
2) identified several proteins involved in insulin secretion such as the subunits of the KATP 
channel Kir6.2 and SUR1 and the secretory vesicle protein granuphilin, which possesses a C2 
domain capable of binding the phosphoinositide PIP2 [50]. Another binding partner, PTBP1 
(Polypyrimidine tract-binding protein 1), regulates the translation of insulin granule proteins in 
response to glucose [37]. The potential regulation by STARD10 of the activity of this protein 
could conceivably affect granule structure.   
 
We also considered the possibility that altered granule composition may reflect altered 
intracellular Zn2+ levels given that similar changes are observed after deletion of the  gene 
encoding the Zn2+ transporter ZnT8, Slc30a8 [51]. Thus, total Zn2+ content, likely reflecting 
intragranular Zn2+, assessed by ICP/MS, was increased in islets of βStard10KO vs. WT mice 
(Figure 1). The latter appears unlikely to be due to changes in the expression of ZnT8 (encoded 
by Slc30a8), which we did not observe, but might reflect altered intrinsic activity, or granule 
recruitment, of ZnT8 due to altered membrane lipid composition [52]. Consistent with this 
possibility, anionic phosphatidylinositols increase,  whereas non bilayer phospholipids 
(promoting membrane curvature) lysophosphatidylcholine (LPC) and phosphatidylethanolamine 
(PE), lower ZnT8 activity [52]. 
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An unexpected finding from the current study is that βStard10KO islets secreted more 
radiolabeled proinsulin versus WT after 4 h of chase in 5.5 mM glucose medium, whilst no 
difference was observed between genotypes at 20 mM glucose. These results contrast with a 
decrease in the proinsulin:insulin ratio observed in plasma from βStard10KO mice [10] and a 
similarly lowered ratio in human risk variant carriers versus controls [22]. One possible 
explanation is that increased proinsulin secretion in unstimulated cells may enrich for storage of 
mature, processed insulin, hence producing a lowered proinsulin:insulin release during 
stimulation with high glucose. According to studies using radioactive labelling [53] or live cell 
imaging of a SNAP-tag fused with insulin [54], young, newly synthesised insulin granules are 
preferentially secreted upon glucose stimulation. Given their reduced transit time, the proportion 
of unprocessed proinsulin in the young granules could be higher than in older ones. Other 
evidence points towards the existence of vesicular trafficking pathways leading to unstimulated, 
“constitutive-like” secretion of proinsulin [55]. It has been speculated [56] that this involves 
routing to the endosomal compartment and either cargo degradation in the lysosome, or secretion 
at the plasma membrane through a “constitutive-like” pathway [57]. By changing the lipid 
composition of granules, STARD10 may modulate their trafficking properties, affect the age of 
secreted granules and/or decrease their targeting to the lysosomes.  
 
A striking finding of our studies is the change in lipid composition observed in the βStard10KO 
islets (Figure 3). Although it was not possible to assess which intracellular membranes may be 
affected given the limited sensitivity of the bulk analysis performed, we note that an excess of 
cholesterol has previously been shown to inhibit insulin exocytosis [58,59] and former studies 
points towards a role for phosphoinositide signalling in insulin secretion [60,61]. The PI 
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transporter TMEM24 regulates pulsatile insulin secretion by replenishing the phosphoinositide 
pool at the endoplasmic reticulum-plasma membrane contact sites [62]. It is thus tempting to 
speculate that STARD10 might affect insulin secretion in a similar fashion.  
 
In conclusion, we identify phosphatidylinositols as potential new ligands for STARD10. 
Changes in STARD10 expression in carriers of type 2 diabetes risk alleles may consequently 
affect the lipid composition, alter β-cell granule maturation, and, ultimately, insulin synthesis and 
secretion. 
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Figure 1: βStard10KO β-cells display altered granule morphology  
A, Representative Transmission Electron Microscopy images of Cre- and Cre+ β-cells. Red 
arrowhead: granules with a “rod-shaped” core. Scale bar = 1μm. B, “Rod-shaped” core granule 
numbers are increased in the βStard10KO β-cells (n = 3 animals, 6 images per animal; p<0.001, 
Student’s t-test). C, β-cell granule diameter (nm) (n = 42 images from 3 animals, p<0.001, 
Student’s t-test). D, β-cell granule “circularity” (n = 42 images from 3 animals, p<0.05, Welch’s 
t-test). E, β-cell granule density (n = 19 images from 3 animals, ns, Mann-Whitney test). F, β-cell 
morphologically docked granules (per μm plasma membrane) (n = 18 images from 3 animals, ns, 
Mann-Whitney test). G, Representative trace for β-cell expressing the cytosolic eCALWY4 Zn2+ 
sensor. Steady state fluorescence intensity ratio (citrine/cerulean) (1, R) was first measured 
before the maximum ratio (2, Rmax) was obtained under perfusion with buffer containing 50 μM 
TPEN (zinc-free condition). Finally, the minimum ratio (3, Rmin) was obtained under perfusion 
with buffer containing 5 μM pyrithione and 100 μM Zn2+ (zinc-saturated condition). Cytosolic 
free Zn2+ concentrations were calculated using the formula: (R-Rmin)/(Rmax-Rmin). H, 
Cytosolic Zn2+ concentrations measured by eCALWY4 in Cre- and Cre+ β-cells (n = 33 – 65 
cells per genotype, ns, Mann-Whitney test). I, Total islet zinc measured by inductively coupled 
plasma mass spectrometry (ICP/MS) in Cre- and Cre+ animals (n = 4 animals/genotype, 
*p<0.05, unpaired t-test) 
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Figure 2: Deletion of Stard10 increased basal secretion of newly synthesised proinsulin but 
did not affect total secreted proinsulin:insulin ratio 
A, Representative phosphorimages from reducing gels representing 35S-labelled proinsulin and 
insulin (B chain) originating from cell lysate (C) or secreting medium (M) samples after 1.5 or 
4 h of chase in 5.5 mM glucose medium. B, Secreted proinsulin after 1.5 or 4 h of chase in 
5.5 mM glucose medium expressed as percentage of total labelled proinsulin (n = 4-5 animals; 
*p<0.05, Mann Whitney test). C, Secreted proinsulin:insulin ratio after 1.5 or 4 h of chase in 
5.5 mM glucose medium (n = 4-5 animals; *p<0.05, Mann Whitney test). D, Fraction of stored 
processed insulin remaining inside the cells after 1.5 or 4 h of chase in 5.5 mM glucose medium 
(n = 4-5 animals; ns, Mann Whitney test). E, Cellular proinsulin:insulin ratio after 1.5 or 4 h of 
chase in 5.5 mM glucose medium (n = 4-5 animals; ns, Mann Whitney test). F, Representative 
phosphorimages from reducing gels representing 35S-labelled proinsulin and insulin (B chain) 
originating from cell lysate (C) or secreting medium (M) samples after 30 min. of chase in 
20 mM glucose medium. G, Secreted proinsulin after 30 min. of chase in 20 mM glucose 
medium expressed as percentage of total labelled proinsulin (n = 4-5 animals; ns, Mann Whitney 
test). H, Secreted proinsulin:insulin ratio after 30 min. of chase in 20 mM glucose medium (n = 
4-5 animals; ns, Mann Whitney test). Quantification for B, C, D, E, G and H was done on the 
phosphorimages obtained from reducing gels. I, Secreted total proinsulin:insulin ratio after 
30 min. secretion by isolated islets in 3 or 17 mM glucose Krebs-HEPES-bicarbonate buffer.  
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Figure 3: Altered lipidomic profile in βStard10KO islets   
The deletion of Stard10 in mouse pancreatic β-cells significantly increased total cholesteryl 
esters, phosphatidylinositols and the phosphatidylethanolamine species 34:0 in islets (n = 5 
animals; *p<0.05, **p<0.01, paired t-test) 
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Figure 4: Identification of differentially-regulated genes in βStard10KO islets by RNA seq 
A, 20 first differentially regulated genes in βStard10KO, ranked by increasing adjusted p-value 
with their relative expression versus WT (log2 fold change, n = 6 animals per genotype) 
B, Genes identified by the GO consortium as component of “neuron projection” and “neuron 
part”, found enriched among the downregulated genes identified in the βStard10KO islets, shown 
as relative expression versus WT (log2 fold change). Neither β-cell signature genes (C) nor 
“disallowed” β-cell gene family (D) were differentially regulated in βStard10KO vs. WT islets.  
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Figure 5. Phosphoinositide binding to STARD10 
A, Coomassie blue staining of 6His-MBP-STARD10 (75kDa) purified by Immobilised Metal 
Affinity column (IMAC): FT: Flow-Through, W1: first column wash, W5: last column wash, E: 
elution. B, Lipid overlay assay. LPA, lysophosphatidic acid; S1P, Sphingosine-1-phosphate; 
LPC, Lysophosphatidylcholine; PI, Phosphatidylinositol; PI(3)P, PI-(3)-phosphate; PI(4)P, PI-
(4)-phosphate; PI(5)P, PI-(5)-phosphate; PE, Phosphatidylethanolamine; PC, 
Phosphatidylcholine; PI(3,4)P2, PI-(3,4)-bisphosphate; PI(3,5)P2, PI-(3,5)-bisphosphate; 
PI(4,5)P2, PI-(4,5)-bisphosphate; PIP(3,4,5)P3, PI-(3,4,5)-trisphosphate; PA, Phosphatidic acid; 
PS, Phosphatidylserine. Immunodetection of bound protein was performed using a primary anti-
STARD10 antibody (Santa Cruz) and a secondary anti-goat-HRP antibody (Santa Cruz). 
STARD10 bound to all PIP species. 
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Figure 6. Structure of H. sapiens STARD10  
A, Three-dimensional view of the crystal structure of unliganded human STARD10: ribbon 
diagram colored from the N-terminus (blue) to the C-terminus (red). B, Docking of 
phosphatidyl-inositol 3 phosphate (PI(3)P) to the human STARD10 structure. STARD10 cavity 
is larger than the phosphatidylcholine transporter protein STARD2 and contrary to the latter 
readily accommodates phosphatidylinositols. 
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Table 1 RNA seq identification of differentially regulated genes in βStard10KO islets 
20 first differentially regulated genes in βStard10KO, ranked by increasing adjusted p-value 
(padj) with their relative expression versus WT (log2 fold change) 
 
symbol log2FoldChange pvalue padj entrezID 
ENSMUSG00000030688 Stard10 -1.3455 1.13E-161 1.71E-157 56018 
ENSMUSG00000035804 Ins1 -0.5451 1.46E-17 1.11E-13 16333 
ENSMUSG00000050711 Scg2 0.2439 2.13E-13 1.07E-09 20254 
ENSMUSG00000043639 Rbm20 0.4753 3.35E-12 1.27E-08 73713 
ENSMUSG00000028989 Angptl7 0.4761 1.40E-10 4.23E-07 654812 
ENSMUSG00000034472 Rasd2 0.4568 2.99E-10 7.52E-07 75141 
ENSMUSG00000048070 Pirt -0.4203 1.71E-09 3.68E-06 193003 
ENSMUSG00000038112 AW551984 -0.3837 5.31E-09 1.00E-05 244810 
ENSMUSG00000000386 Mx1 0.4094 3.87E-08 6.49E-05 17857 
ENSMUSG00000019189 Rnf145 0.1714 1.22E-07 0.000185 74315 
ENSMUSG00000025085 Ablim1 0.2650 1.69E-07 0.000232 226251 
ENSMUSG00000007946 Phox2a -0.3054 2.01E-07 0.000253 11859 
ENSMUSG00000032269 Htr3a -0.3423 2.37E-07 0.000276 15561 
ENSMUSG00000029361 Nos1 -0.3533 4.34E-07 0.000468 18125 
ENSMUSG00000092035 Peg10 -0.2823 8.04E-07 0.00081 170676 
ENSMUSG00000051855 Mest -0.3041 1.06E-06 0.000999 17294 
ENSMUSG00000025348 Itga7 -0.3500 1.38E-06 0.001223 16404 
ENSMUSG00000029219 Slc10a4 -0.2939 1.53E-06 0.00128 231290 
ENSMUSG00000034981 Parm1 -0.3002 1.89E-06 0.001502 231440 
ENSMUSG00000060519 Tor3a 0.1692 2.98E-06 0.002254 30935 
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Table 2 STARD10 binding partners identified by mass spectrometry in INS1 (832/13) cells 
20 most significantly enriched proteins found in the STARD10 pull down condition versus 
control IgG with a cut-off of at least 5 unique peptides identified. 
 
 
 
 
Appendix A. Supplementary data 
Accession Gene 
symbol 
log2 
FoldChange FDR Protein name 
G3V702 Smu1 4.1143 0.002426 Smu-1 suppressor of mec-8 and unc-52 homolog (C. elegans) 
Q56A27 Ncbp1 4.4449 0.002435 Nuclear cap-binding protein subunit 1 
Q63570 Psmc4 3.7556 0.006621 26S proteasome regulatory subunit 6B 
F1LX68 Spats2 4.2439 0.006621 Spermatogenesis-associated, serine-
rich 2 
Q3B8Q1 Ddx21 3.1883 0.006621 Nucleolar RNA helicase 2 
A0A0G2QC21 Arhgef7 5.1017 0.006621 Rho guanine nucleotide exchange factor 7 
Q5XIW8 Sart1 3.6068 0.006621 U4/U6.U5 tri-snRNP-associated protein 1 
Q6AYI1 Ddx5 3.5220 0.006621 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 
P62718 Rpl18a 5.3046 0.006621 60S ribosomal protein L18a 
Q4FZT9 Psmd2 5.0539 0.006621 26S proteasome non-ATPase 
regulatory subunit 2 
P62198 Psmc5 5.1616 0.006621 26S proteasome regulatory subunit 8 
G3V8B6 Psmd1 3.6940 0.006621 26S proteasome non-ATPase 
regulatory subunit 1 
P70673 Kcnj11 5.1478 0.007165 ATP-sensitive inward rectifier potassium channel 11 
Q3B8Q2 Eif4a3 5.3478 0.007229 Eukaryotic initiation factor 4A-III 
Q5XIH7 Phb2 4.8776 0.007229 Prohibitin-2 
P62193 Psmc1 5.0757 0.007229 26S proteasome regulatory subunit 4 
M0R735 Syncrip 5.9137 0.007229 Heterogeneous nuclear 
ribonucleoprotein Q 
A0A0G2JTI7 Prpf3 4.0762 0.007229 Pre-mRNA-processing factor 3 
D4A0U3 Zfp638 3.6588 0.007229 Zinc finger protein 638 
D3ZZR5 Snrpa1 2.4835 0.007229 Small nuclear ribonucleoprotein polypeptide  
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